Semagacestat Is a Pseudo-Inhibitor of γ-Secretase
Authors:
Open Access
- 1 October 2017
- journal article
- Published by Elsevier in Cell Reports
- Vol. 21 (1) , 259-273
Abstract
No abstract availableKeywords
Funding Information
- Niigata University
- Ministry of Education, Culture, Sports, Science and Technology (2017-2808, T243902830, T254617660, T254617680, T264617450, T264617460)
- SENSHIN Medical Research Foundation
This publication has 47 references indexed in Scilit:
- Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNAScientific Reports, 2013
- RNA-Guided Human Genome Engineering via Cas9Science, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Phase I Trial of MK-0752 in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium StudyJournal of Clinical Oncology, 2011
- A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous systemAnnals of Neurology, 2009
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer DiseaseArchives of Neurology, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- L-685,458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid β-Protein Precursor γ-Secretase ActivityBiochemistry, 2000
- Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril proteinBiochemical and Biophysical Research Communications, 1984